Röth, Alexander

Immune Activation in Patients With Irritable Bowel Syndrome

Liebregts, T., Adam, B., Bredack, C., Röth, A., Heinzel, S., Lester, S., Downie–Doyle, S., Smith, E., Drew, P., Talley, N. J., et al. (2007) · Gastroenterology

Gastrointestinal motility and disordersGut microbiota and health

Cited by 660

Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria

Hillmen, P., Szer, J., Weitz, I., Röth, A., Höchsmann, B., Panse, J., Usuki, K., Griffin, M., Kiladjian, J.-J., de Castro, C., et al. (2021) · New England Journal of Medicine

Complement system in diseasesHemophilia Treatment and Research

Cited by 440

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: An open-label, single-arm, phase 2, proof-of-concept trial

Risitano, A. M., Röth, A., Soret, J., Frieri, C., de Fontbrune, F. S., Marano, L., Alashkar, F., Benajiba, L., Marotta, S., Rozenberg, I., et al. (2021) · The Lancet Haematology

Complement system in diseasesHemophilia Treatment and Research

Cited by 110